不同菌种来源左旋门冬酰胺酶及不同用法不良反应的观察  

Side effects of L-asparaginase with different sources and administrations

作　　者：王华[1] 耿其荣[1] 吕跃[1] 

机构地区：[1]中山大学肿瘤防治中心华南肿瘤学国家重点实验室血液肿瘤科,广州510060

出　　处：《广东医学》2011年第24期3260-3262,共3页Guangdong Medical Journal

摘　　要：目的比较欧文菌株与埃希大肠杆菌株来源、连用与隔日使用左旋门冬酰胺酶(L-asparaginase,L-ASP)的不良反应发生情况。方法采用病例分析方法,比较欧文菌株与埃希大肠杆菌株来源L-ASP以及L-ASP连用与隔日使用肝功能、凝血三项(PT、APTT、TT)、纤维蛋白原以及血浆白蛋白、血糖的变化,所需输注的血浆量。结果欧文菌株与埃希大肠杆菌株来源L-ASP相比,后者所需输注新鲜血浆量高于前者,不良反应发生率差异无统计学,连用与隔日使用差异无统计学意义。结论欧文菌株与埃希大肠杆菌株来源L-ASP具有相似的安全性。连用与隔日使用L-ASP治疗急性淋巴细胞白血病和淋巴母细胞淋巴瘤同样安全。Objective To investigate the side effects of L - asparagninase （ L - ASP） from 2 different sources, Erwinia and Escherichia coli, with consecutive or every - other - day usage. Methods Liver function, blood clotting, （PT, APTT, TT）, fibrinogen concentration, albumin, blood glucose and plasma infusion were recorded for analysis. Resuits Significantly more fresh plasma infusion was required in use of Escherichia coli - asparaginase than that of Erwinia - asparaginasc. There was no significant difference in side effects, between consecutive day and every other day administrations. Conclusion Erwinia - asparaginase and Escherichia coli - asparaginase have the same safety in consecutive or every other day use in treating acute lymphoid leukemia and iymphoblastic lymphoma.

关 键 词：左旋门冬酰胺酶 欧文菌株 埃希大肠杆菌 不良反应 淋巴系统肿瘤 

分 类 号：R733.71[医药卫生—肿瘤]